Dana-Farber Cancer Institute shared a post on LinkedIn:
“We have been awarded an extraordinary $20 million grant to advance metastatic breast cancer research from the Elaine and Eduardo Saverin Foundation.
“We’re grateful to the Saverin Family for their incredible contributions to our metastatic breast cancer research program and infrastructure which will significantly impact the productivity and success of our work in late-stage breast cancer,” said Sara Tolaney, MD, MPH, chief of the division of breast oncology.
This grant will allow us to focus on therapeutic innovation across key areas in metastatic breast cancer including:
– Optimizing clinical trials to identify biomarkers of response and resistance and rapidly translate promising preclinical strategies into patient studies.
– Continuing the Saverin Research Awards to seed the most innovative investigations in metastatic breast cancer led by Dana-Farber physician-scientists.
– Expanding resources and infrastructure to integrate and analyze clinical, genomic, and imaging from more than 20,000 patients and counting.
– Harnessing AI to predict outcomes, personalize therapies, understand tumor-immune interactions, and identify resistance mechanisms.
– Advancing liquid diagnostics to detect early recurrence and personalize therapy in metastatic settings.
To learn more about the impacts of the Saverin Foundation’s grant, visit.”
More posts featuring Dana-Farber Cancer Institute on OncoDaily.